TAMPA, Fla.--(Xcelience LLC, a Tampa-based contract development and manufacturing organization, announced today the grand opening of a new 24,000 sq. ft. facility, located south of the Tampa airport at 4901 Grace Street, on Friday, September 14th between 2 and 5 p.m.)--
“What I love about this building is that it was designed for our customers, with our customers”
The new building is purpose-built for primary and secondary packaging, and contains five secondary and four primary packaging rooms, in addition to labeling, warehouse and storage facilities. It will be audited and approved for clinical trial work both domestically and in Europe.
“What I love about this building is that it was designed for our customers, with our customers,” says Derek Hennecke, President and CEO of Xcelience. “Our clients asked us to move into clinical supplies, and we did. We expanded gradually, being careful to enter the new area with the same agility and service mentality that has always defined our work. When the job began to outgrow our current facility, we asked our clients what their ideal facility would look like. This is the result.”
“By streamlining our services,” adds Ted Koontz, COO, “we can take a molecule from pre-formulation through formulation and clinical manufacturing straight to packaging, labeling and shipping, all as part of a single project within a single organization. The result is a quicker, more cost-effective and hassle-free process for our clients.”
Xcelience, which has doubled its headcount over the last three years, will be celebrating the hiring of its 100th employee next month. The company projects it will hire another 100 employees over the next three years.
“Tampa’s been called one of the best places to do business. Our health sciences cluster is creating the jobs of the future,” said Tampa Mayor Bob Buckhorn. “I am proud Xcelience calls Tampa home, and congratulate them on the opening of their second facility here.”
"Xcelience has been a wonderful addition to our business community, and we’re pleased to join them in celebrating the opening of their new facility,” said Rick Homans, President and CEO of the Tampa Hillsborough Economic Development Corporation. “Their continued growth and expansion is a testament to the quality of our workforce, and their presence is a significant asset as we work to expand our life sciences industry.”
Confirmed guests for the ceremony in addition to staff, clients, and corporate partners include Honorable Jack Latvala, Florida Senate, Tampa Mayor Bob Buckhorn, Honorable Al Higginbotham, Hillsborough County Board of County Commissioners, Honorable Dana Young, Florida House of Representatives, Julie Fitzpatrick from the office of Congresswoman Kathy Castor, and supporting members from the Tampa Hillsborough Economic Development Corporation and the Tampa Bay Partnership.
Xcelience wishes to thank the Florida institutions which have offered continued economic stimulation and sustained capital investment to Xcelience and other Florida companies like it. In particular:
The Tampa Hillsborough Economic Development Corporation — officially designated by Enterprise Florida as Hillsborough County’s primary business recruitment economic development team; and
The Tampa Bay Partnership — a CEO-led regional economic development organization with a mission to work with its partners to market the region nationally and internationally, to conduct regional research, and to coordinate efforts to influence business and government issues that impact economic growth and development.
About Xcelience LLC
Xcelience LLC (www.xcelience.com) is a premier provider of formulation development and clinical supplies solutions with a solid reputation for accelerating early-phase clinical development. The company’s outstanding quality record, drug-development expertise, disciplined project management, and willingness to customize enables delivery of real advantages to pharmaceutical innovators focused on small-molecule development.
Partnering with a specialist for early development can accelerate development timelines and streamline the supply chain. Since 1997, Xcelience has been reliably expediting drug development and reducing compound risk. Company scientists have specialized experience in overcoming challenging physical and chemical properties while achieving improved solubility and compound bioavailability.